Cipher To Appeal “Approvable” Letter for CIP-Isotretinoin
This article was originally published in The Pink Sheet Daily
Executive Summary
Toronto firm maintains agency’s request for additional clinical data has already been addressed in existing NDA package.
You may also be interested in...
Dispute Resolution Upholds FDA Request For New CIP-Isotretinoin Study From Cipher
Canadian firm is considering its options, CEO says.
Dispute Resolution Upholds FDA Request For New CIP-Isotretinoin Study From Cipher
Canadian firm is considering its options, CEO says.
Cipher Seeks Meeting With FDA To Discuss Tramadol “Approvable” Letter
Agency asks for additional efficacy trial for the extended-release opioid analgesic.